|Specialties||Acupuncture | Naturopathic Medicine | Traditional Chinese Medicine | Integrative Medicine|
|Conditions||Eye Diseases | Glaucoma | Macular Degeneration | Retinitis Pigmentosa|
Dr. Andy Rosenfarb, founder and clinical director of Acupuncture Health Associates in Westfield, NJ, is a world-renowned expert in the field of of Chinese Medical Opthalmology. Since 1997, he has been leading the field in integrated treatment methods that combine Traditional Chinese Medicine, Naturopathic Medicine and new cutting-edge therapies to help people suffering from debilitating eye diseases to maintain and improve their eyesight. Dr. Rosenfarb earned his Master’s in Traditional Chinese Medicine from Pacific College of Oriental Medicine and his Doctor of Naturopathy from Canyon College. He continued his post-graduate education at Zhejiang College of Chinese Medicine in Hangzhou, China.
Drawing from his extensive training and clinical experience, Dr. Rosenfarb recently teamed with researchers at John Hopkins University to design the acupuncture protocol for the first-ever clinical study on the efficiency of treating RP with acupuncture. Dr. Rosenfarb is Board Certified in Acupuncture and Chinese Herbal Medicine, and is a founding member of the National Guild for Acupuncture. He serves on the Board of Directors for the American Association for Acupuncture and Oriental Medicine (AAAOM), and as an Executive Council Member of the Specialty Committee of Ophthalmology, of the World Federation of Chinese Medicine. He is the co-author of four books, Healing Your Eyes with Chinese Medicine, Ophthalmology in Chinese Medicine, Acupuncture Treatment for Retinitis Pigmentosa, Acupuncture Treatment for Macular Degeneration, and The Black Book of Micro Acupuncture 48: Forty-Eight New Acupuncture Points to Unleash the Power of Healing.
Dr. Rosenfarb recently teamed with researchers at Johns Hopkins University on the first ever clinical study to determine the efficacy of treating Retinitis Pigmentosa with acupuncture and other TCM therapies. Dr. Rosenfarb drew on his extensive training and clinical experience to develop the treatment protocol and trained staff at Johns Hopkins University to administer it to study participants.
Based on the success of that initial study, the NIH is funding a second, expanded clinical study in 2014 that will once again utilize Dr. Rosenfarb’s treatment protocol. The first peer-reviewed study was recently published in Clinical and Experimental Optometry.